Integration of PDX Modeling & Pharmacokinetics to Inform Clinical Development of the Novel ATM inhibitor WSD0628
Time: 11:30 am
day: Day Two
Details:
- Use of in vitro and PDX modeling to define target drug concentrations for a novel ATM inhibitor WSD0628
- Integration of Kp and Kpuu to define target human plasma concentrations for robust radiosensitization in GBM
- Analysis of human PK data to inform further dose-escalation in the first-inhuman clinical trial of WSD0628 and radiation in recurrent GBM the translation of synthetic lethal strategies into clinical therapies for improved patient outcomes
